$PCRX
Pacira Biosciences Inc Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000139681424000045 Filed on May 07, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$178.0M	$167.1M	$160.3M
YoY Change	5.05%	4.23%	1.49%
Cost Of Revenue	$44.26M	$47.42M	$49.02M
YoY Change	-8.18%	-3.27%	35.89%
Gross Profit	$133.8M	$119.7M	$111.3M
YoY Change	10.31%	7.53%	-8.69%
Gross Profit Margin	75.14%	71.63%	69.43%
Selling, General & Admin	$68.13M	$72.03M	$70.84M
YoY Change	5.05%	1.67%	10.24%
% of Gross Profit	50.93%	60.17%	63.64%
Research & Development	$20.34M	$18.24M	$17.14M
YoY Change	8.04%	6.41%	-20.67%
% of Gross Profit	15.2%	15.24%	15.4%
Depreciation & Amortization	$4.500M	$18.43M	$19.60M
YoY Change	-76.38%	-6.0%	-2.15%
% of Gross Profit	3.36%	15.39%	17.61%
Operating Expenses	$88.46M	$90.26M	$87.98M
YoY Change	-9.73%	2.59%	2.47%
Operating Profit	$28.24M	$13.21M	-$3.091M
YoY Change	21.39%	-527.43%	-117.77%
Interest Expense	$865.0K	$3.316M	$9.589M
YoY Change	-149.32%	-65.42%	-6.41%
% of Operating Profit	3.06%	25.1%
Other Income/Expense, Net	$8.344M	$428.0K	-$23.38M
YoY Change	-3201.86%	-101.83%	131.54%
Pretax Income	$36.58M	$13.64M	-$26.47M
YoY Change	-3.35%	-151.52%	-462.96%
Income Tax	$17.70M	$4.661M	-$6.938M
% Of Pretax Income	48.38%	34.17%
Net Earnings	$18.89M	$8.979M	-$19.54M
YoY Change	-26.69%	-145.96%	-386.12%
Net Earnings / Revenue	10.61%	5.37%	-12.18%
Basic Earnings Per Share	$0.41	$0.19	-$0.43
Diluted Earnings Per Share	$0.39	$0.19	-$0.43
COMMON SHARES
Basic Shares Outstanding	46.55M shares	46.50M shares	45.95M shares
Diluted Shares Outstanding	50.54M shares	52.19M shares	45.95M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$404.2M	$325.9M	$174.0M
YoY Change	83.1%	87.29%	-61.52%
Cash & Equivalents	$247.1M	$184.1M	$35.55M
Short-Term Investments	$157.2M	$141.8M	$138.5M
Other Short-Term Assets	$19.77M	$18.80M	$15.93M
YoY Change	13.96%	18.01%	-16.4%
Inventory	$103.4M	$96.78M	$92.98M
Prepaid Expenses
Receivables	$104.8M	$101.6M	$93.21M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$632.2M	$543.1M	$376.1M
YoY Change	47.26%	44.4%	-43.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$168.9M	$171.8M	$181.6M
YoY Change	-31.4%	-5.4%	-4.29%
Goodwill	$163.2M	$163.2M	$163.2M
YoY Change	0.0%	0.0%	12.01%
Intangibles	$454.6M	$468.9M	$526.2M
YoY Change	-11.19%	-10.89%	-13.68%
Long-Term Investments	$36.50M	$36.54M	$40.57M
YoY Change	2.45%	-9.92%	13.41%
Other Assets	$135.1M	$141.1M	$167.6M
YoY Change	-13.45%	-15.82%	-1.01%
Total Long-Term Assets	$1.015B	$1.040B	$1.147B
YoY Change	-8.85%	-9.33%	-6.3%
TOTAL ASSETS
Total Short-Term Assets	$632.2M	$543.1M	$376.1M
Total Long-Term Assets	$1.015B	$1.040B	$1.147B
Total Assets	$1.647B	$1.583B	$1.523B
YoY Change	6.77%	3.93%	-19.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.73M	$8.982M	$17.26M
YoY Change	-22.62%	-47.96%	16.29%
Accrued Expenses	$64.81M	$66.82M	$61.63M
YoY Change	-0.6%	8.41%	-29.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$8.641M	$10.85M
YoY Change	-100.0%	-20.38%	-94.4%
Total Short-Term Liabilities	$92.69M	$93.44M	$98.70M
YoY Change	-14.89%	-5.32%	-67.65%
LONG-TERM LIABILITIES
Long-Term Debt	$589.3M	$511.7M	$542.9M
YoY Change	10.73%	-5.75%	-25.6%
Other Long-Term Liabilities	$13.01M	$12.69M	$11.58M
YoY Change	-86.06%	9.59%	7.99%
Total Long-Term Liabilities	$13.01M	$12.69M	$11.58M
YoY Change	-97.92%	9.59%	7.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$92.69M	$93.44M	$98.70M
Total Long-Term Liabilities	$13.01M	$12.69M	$11.58M
Total Liabilities	$767.5M	$691.2M	$755.4M
YoY Change	4.51%	-8.5%	-36.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$78.93M	-$97.82M	-$168.3M
YoY Change	-44.62%	-41.87%	6.62%
Common Stock	$47.00K	$47.00K	$46.00K
YoY Change	2.17%	2.17%	2.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$879.3M	$892.2M	$768.0M
YoY Change
Total Liabilities & Shareholders Equity	$1.647B	$1.583B	$1.523B
YoY Change	6.77%	3.93%	-19.46%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$18.89M	$8.979M	-$19.54M
YoY Change	-26.69%	-145.96%	-386.12%
Depreciation, Depletion And Amortization	$4.500M	$18.43M	$19.60M
YoY Change	-76.38%	-6.0%	-2.15%
Cash From Operating Activities	$53.24M	$49.10M	$19.13M
YoY Change	22.38%	156.7%	-37.85%
INVESTING ACTIVITIES
Capital Expenditures	$1.590M	$2.836M	$6.565M
YoY Change	-53.29%	-56.8%	-14.38%
Acquisitions
YoY Change
Other Investing Activities	-$13.62M	-$12.69M	$72.75M
YoY Change	-226.98%	-117.45%	-136.31%
Cash From Investing Activities	-$15.22M	-$15.53M	$66.18M
YoY Change	-307.68%	-123.47%	-131.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	24.98M	-$2.817M	-$153.9M
YoY Change	5577.27%	-98.17%	-15.24%
NET CHANGE
Cash From Operating Activities	53.24M	$49.10M	$19.13M
Cash From Investing Activities	-15.22M	-$15.53M	$66.18M
Cash From Financing Activities	24.98M	-$2.817M	-$153.9M
Net Change In Cash	63.00M	$30.75M	-$68.59M
YoY Change	22.89%	-144.83%	-80.88%
FREE CASH FLOW
Cash From Operating Activities	$53.24M	$49.10M	$19.13M
Capital Expenditures	$1.590M	$2.836M	$6.565M
Free Cash Flow	$51.65M	$46.27M	$12.56M
YoY Change	28.81%	268.26%	-45.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	8979000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	989780000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	976633000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97817000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-106796000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	152000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	247000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	892162000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	870130000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1583321000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1574386000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	167117000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	160341000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	47416000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	49020000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18238000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17140000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	72026000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	70843000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14322000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14322000	usd
CY2024Q1	pcrx	Acquisition Related Gain Loss Charges Impairment And Other AcquisitionRelatedGainLossChargesImpairmentAndOther	1903000	usd
CY2023Q1	pcrx	Acquisition Related Gain Loss Charges Impairment And Other AcquisitionRelatedGainLossChargesImpairmentAndOther	12107000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	153905000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	163432000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	13212000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3091000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3903000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3142000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	3316000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	9589000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-16926000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-159000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	428000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23383000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13640000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26474000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4661000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6938000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	8979000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-19536000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46499000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45949000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52193000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45949000	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	8979000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-19536000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-108000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	251000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	13000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-8000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-95000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	243000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	8884000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19293000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	870130000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13151000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-95000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	892162000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	775010000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	334000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11990000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	243000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	768041000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-19536000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3463000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7342000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18426000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19602000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	681000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	937000	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	24000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	675000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-16926000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	13151000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11990000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3806000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	11618000	usd
CY2024Q1	us-gaap	Provision For Other Losses ProvisionForOtherLosses	73000	usd
CY2023Q1	us-gaap	Provision For Other Losses ProvisionForOtherLosses	-23000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3917000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5192000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7572000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3086000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-897000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1926000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6976000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2628000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3471000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-25120000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-771000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	421000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	49101000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	19128000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2836000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6565000	usd
CY2024Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	56055000	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	49497000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	43361000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	126245000	usd
CY2024Q1	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	usd
CY2023Q1	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	4000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15530000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	66183000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	333000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2024Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	149550000	usd
CY2024Q1	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
CY2023Q1	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	5750000	usd
CY2024Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	usd
CY2023Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1163000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2817000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-153905000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	30754000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-68594000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153298000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104139000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184052000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35545000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	3969000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	17634000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-245000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	201000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	607000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2252000	usd
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	51608000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	54099000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	18764000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	31215000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	26410000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	19039000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	96782000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	104353000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	292258000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	309233000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	120454000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	135306000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	171804000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	173927000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	4100000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	5300000	usd
CY2024Q1	us-gaap	Asset Retirement Obligation AssetRetirementObligation	3900000	usd
CY2023Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	4300000	usd
CY2024Q1	pcrx	Number Of Leases NumberOfLeases	2	lease
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	3497000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	3628000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	494000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	567000	usd
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	131000	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	153000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	3860000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	4042000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	3219000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	3763000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M21D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M9D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0701
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0703
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	9777000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12775000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	12814000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12587000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10925000	usd
CY2024Q1	pcrx	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	16426000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	75304000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13855000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	61449000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	163200000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	163200000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	590090000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	156020000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	434070000	usd
CY2024Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	624956000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	156020000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	468936000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	590090000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	141698000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	448392000	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	624956000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	141698000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	483258000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14300000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14300000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	43000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	57300000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	57300000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	57300000	usd
CY2024Q1	pcrx	Finite Lived Intangible Asset Expected Amortization Year Six FiniteLivedIntangibleAssetExpectedAmortizationYearSix	57300000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	57300000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	57300000	usd
CY2024Q1	pcrx	Finite Lived Intangible Asset Expected Amortization Year Seven FiniteLivedIntangibleAssetExpectedAmortizationYearSeven	37400000	usd
CY2024Q1	pcrx	Finite Lived Intangible Asset Expected Amortization Year Eight FiniteLivedIntangibleAssetExpectedAmortizationYearEight	7900000	usd
CY2024Q1	pcrx	Finite Lived Intangible Asset Expected Amortization Year Nine FiniteLivedIntangibleAssetExpectedAmortizationYearNine	2200000	usd
CY2024Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3311000	usd
CY2023Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9350000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	681000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	937000	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	24000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	675000	usd
CY2024Q1	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	700000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	3316000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	9589000	usd
CY2024Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0296
CY2023Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0536
CY2024Q1	us-gaap	Share Price SharePrice	29.22
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	21192000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	6758000	usd
CY2023	pcrx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Foreign Currency Gain Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetForeignCurrencyGainLoss	61000	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	28011000	usd
CY2024Q1	pcrx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Foreign Currency Gain Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetForeignCurrencyGainLoss	-104000	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	27907000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	141920000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	28000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	110000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	127631000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	111000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	49000	usd
CY2024Q1	us-gaap	Interest Receivable InterestReceivable	100000	usd
CY2023Q4	us-gaap	Interest Receivable InterestReceivable	400000	usd
CY2024Q1	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	wholesaler
CY2023	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	wholesaler
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	200000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13151000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11990000	usd
CY2024Q1	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	6729000	usd
CY2023Q1	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	6464000	usd
CY2024Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	6210000	usd
CY2023Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	5250000	usd
CY2024Q1	pcrx	Compensation Expense From Employee Stock Purchase Plan CompensationExpenseFromEmployeeStockPurchasePlan	212000	usd
CY2023Q1	pcrx	Compensation Expense From Employee Stock Purchase Plan CompensationExpenseFromEmployeeStockPurchasePlan	276000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	13151000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11990000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7079748	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.40
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	900995	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	31.95
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	155397	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	46.84
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	245082	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	50.23
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7580264	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	47.35
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.65
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.85
CY2024Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	8979000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-19536000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	10008000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-19536000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46499000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45949000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52193000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45949000	shares
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8944000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13162000	shares
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	13657000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-27773000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-17000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1299000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13640000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26474000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4661000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6938000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.34
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.26
CY2023Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	1000000	usd
CY2024Q1	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	1000000	usd
CY2024Q1	us-gaap	Restructuring Costs RestructuringCosts	5535000	usd
CY2023Q1	us-gaap	Restructuring Costs RestructuringCosts	0	usd
CY2024Q1	pcrx	Contingent Consideration Gain Loss Restructuring Charges And Other ContingentConsiderationGainLossRestructuringChargesAndOther	-1903000	usd
CY2023Q1	pcrx	Contingent Consideration Gain Loss Restructuring Charges And Other ContingentConsiderationGainLossRestructuringChargesAndOther	-12107000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
CY2024Q1	us-gaap	Restructuring Charges RestructuringCharges	3300000	usd
CY2024Q1	us-gaap	Payments For Reinsurance PaymentsForReinsurance	386000	usd
CY2024Q1	us-gaap	Restructuring Reserve RestructuringReserve	2914000	usd
CY2023Q3	pcrx	Litigation Settlement Amount Expected To Be Awarded From Other Party LitigationSettlementAmountExpectedToBeAwardedFromOtherParty	14500000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001396814-24-000045-index-headers.html	Edgar Link	pending
0001396814-24-000045-index.html	Edgar Link	pending
0001396814-24-000045.txt	Edgar Link	pending
0001396814-24-000045-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pcrx-20240331.htm	Edgar Link	pending
pcrx-20240331.xsd	Edgar Link	pending
pcrx-20240331_g1.jpg	Edgar Link	pending
pcrx-20240331_g2.jpg	Edgar Link	pending
pcrx-3312024xex311.htm	Edgar Link	pending
pcrx-3312024xex312.htm	Edgar Link	pending
pcrx-3312024xex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pcrx-20240331_cal.xml	Edgar Link	unprocessable
pcrx-20240331_def.xml	Edgar Link	unprocessable
pcrx-20240331_lab.xml	Edgar Link	unprocessable
pcrx-20240331_pre.xml	Edgar Link	unprocessable
pcrx-20240331_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira Biosciences Inc Stock $pcrx

2024 Q2 Form 10-Q Financial Statement

#000139681424000045 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira Biosciences Inc Stock $pcrx

2024 Q2 Form 10-Q Financial Statement

#000139681424000045 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira Biosciences Inc Stock $pcrx